%0 Journal Article
%T Evaluation Of Lenalidomide Activity On Glioblastoma Cell Lines In Vitro
%A Melike MUT
%A Gregory POLAR
%A Joan E. CARPENTER
%A Gerard REDPATH
%J Journal of Neurological Sciences
%D 2007
%I Ege University Press
%X Purpose: Thalidomide analog, Lenalidomide (Revlimid ) is a chemotherapeutic agent. In this study, lenalidomide was used in human glioblastoma multiforme (GBM) cell lines to determine its pro-apoptotic, anti-proliferative and radiosensitizing properties. Methods: The GBM cells were treated with lenalidomide [0, 1, 5, 30, 60 ¦ÌM] before ultravioletB (UVB) [0, 50, 100 mj] or ¦Ã -irradiation [0, 5, 20 Gy], and kept in drug for 5 days. Viable cell numbers were determined by trypan blue exclusion. The cell proliferation index was assessed by[ 3H]-Thymidine incorporation. Apoptosis was assessed by flow cytometry with Sub G0 gating and the activation of caspase-8 and caspase-9 after the treatments were completed. Results: Lenalidomide alone or in combination with UVB or ¦Ã-irradiation did not have a significant effect on cell death. Lenalidomide had minimal synergistic effect with ¦Ã-irradiation to reduce cell growth. Lenalidomide when used alone had an insignificant stimulatory effect on cell proliferation in GBM cells at doses 1-30 ¦ÌM. Lenalidomide did not activate caspase-8 or caspase-9 pathways. Conclusions: Lenalidomide had a weak synergistic effect with ¦Ã-irradiation in decreasing cell growth in vitro. It may not be a therapeutic agent in the in the absence of ¦Ã-irradiation for the treatment of GBM.
%K lenalidomide
%K glioblastoma
%K radioterapi
%K thalidomide
%K revlimid
%U http://jns.dergisi.org/pdf/pdf_JNS_140.pdf